Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by StockscoutXon Jun 27, 2021 12:10pm
179 Views
Post# 33457534

RE:Just crazy.

RE:Just crazy. Probably there is a reason why Aristotle has no traction in the general market. There exists already tests that measure the number of cancer cells in the blood for many years now except that it doesn't identify what type like Aristotle. Therefore, it could detect cancer cells that hasn't necessarily multiplied to affect the health of a person. Furthermore, is it necessary to start a cancer treatment not knowing if it will develop or not? Every person from the day we are born to the day we die produce cancer cells that our body usually eliminates them unless our body has a medical condition or environmental condition cause a full blown cancer.

Here is an interesting link:
https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-diagnosis/art-20046459

VerifiedUser123 wrote: We've launched Aristotle and we're at 6 pennies. Why do we even have a CEO. He's clearly not doing his job


<< Previous
Bullboard Posts
Next >>